Traders should monitor upcoming commercial launch timelines and potential payer reimbursement strategies for EpiCapture™, as successful adoption could significantly impact revenue given the large prostate cancer testing market. The 85% AUC is clinically compelling and may drive rapid physician adoption.
Price Chart
Executive Summary
Trinity Biotech announced successful clinical validation of an enhanced version of its EpiCapture™ prostate cancer test, which now incorporates machine learning and patient ethnicity to improve risk prediction accuracy. The test achieved an 85% AUC in a 750-patient study and will be commercialized as a lab-developed test through its New York reference lab, marking the company's strategic entry into precision oncology diagnostics.
Key Facts
- Enhanced EpiCapture™ test achieved 85% clinical accuracy (AUC) in a 750-patient clinical study.
- Test integrates machine learning and patient ethnicity with DNA biomarkers for improved risk prediction of aggressive prostate cancer.
- Will be commercialized as a Laboratory Developed Test (LDT) through Trinity Biotech’s New York reference laboratory.
- Represents Trinity Biotech’s first entry into precision oncology diagnostics.
- Test offers a non-invasive urine-based alternative to MRI and needle biopsy.
Financial Impact
Potential new revenue stream in precision oncology; exact financial impact not quantified but strategically significant given $20B U.S. prostate cancer care market.
Risk Factors
- Commercialization success depends on market acceptance and physician adoption of a new diagnostic modality.
- Reimbursement challenges for a new LDT without established CPT coding or payer coverage.
- Execution risk in scaling lab operations in New York to handle nationwide volume.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260502 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | 6-K | $5.77 | awaiting T+60 | — | $7.30 (+26.52%) |
Sep 9, 2026 6w ago | 6-K | $8.00 | awaiting T+60 | — | $7.30 (−8.75%) |
Sep 2, 2026 7w ago | EFFECT | $9.60 | awaiting T+60 | — | $7.30 (−23.96%) |
Aug 28, 2026 8w ago | 6-K | $9.87 | awaiting T+60 | — | $7.30 (+26.04%) |
Aug 21, 2026 9w ago | F-1/A | $10.60 | awaiting T+60 | — | $7.30 (−31.13%) |
Aug 17, 2026 10w ago | 6-K | $11.17 | awaiting T+60 | — | $7.30 (−34.65%) |
Aug 14, 2026 10w ago | 6-K | $11.67 | awaiting T+60 | — | $7.30 (−37.45%) |
Jul 22, 2026 13w ago | 6-K | $0.3033 $0.2643 | ▼ −12.85% | ▼ −16.11% | $7.30 (+2306.86%) |
Jul 22, 2026 13w ago | 6-K | $0.3033 $0.2643 | ▼ −12.85% | ▼ −16.11% | $7.30 (+2306.86%) |
Jul 2, 2026 16w ago | 6-K | $0.3765 $0.2240 | ▼ −40.50% | ▼ −43.30% | $7.30 (+1838.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers